Iovance   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: New York NY United States (2007)

Organization Overview

First Clinical Trial
2012
NCT01701674
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2024

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Iovance Biotherapeutics | Iovance Biotherapeutics, Inc. | Lion Biotechnologies | Lion Biotechnologies, Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 2)

Bone Neoplasms (Phase 2)

Carcinoma (Phase 2)

Carcinoma, Adenosquamous (Phase 1)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Carcinoma, Ovarian Epithelial (Phase 2)

Carcinoma, Squamous Cell (Phase 2)

Carcinoma, Transitional Cell (Phase 2)

Carcinosarcoma (Phase 2)

Chondrosarcoma (Phase 2)

Colorectal Neoplasms (Phase 2)

Cystadenocarcinoma, Serous (Phase 2)

Giant Cell Tumor of Bone (Phase 2)

Giant Cell Tumors (Phase 2)

Histiocytoma, Malignant Fibrous (Phase 2)

Leukemia (Phase 2)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)

Leukemia, Lymphoid (Phase 2)

Lung Neoplasms (Phase 2)

Lymphoma (Phase 2)

Melanoma (Phase 2)

Neoplasms (Phase 2)

Osteosarcoma (Phase 2)

Ovarian Neoplasms (Phase 2)

Sarcoma (Phase 2)

Skin Neoplasms (Phase 1)

Squamous Cell Carcinoma of Head and Neck (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 21
  • # of Trial APIs: 14